Secretory co-factors in next-generation cellular therapies for cancer

Atsushi Okuma*, Yoshihito Ishida, Taketo Kawara, Shoji Hisada and Shinsuke Araki

Center for Exploratory Research, Research and Development Group, Hitachi Ltd., Kobe, Japan

Since chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies were approved by the U.S. Food and Drug Administration, numerous “next-generation” CAR T cells have been developed to improve their safety, efficacy, and applicability. Although some of these novel therapeutic strategies are promising, it remains difficult to apply these therapies to solid tumors and to control adverse effects, such as cytokine release syndrome and neurotoxicity. CAR T cells are generated using highly scalable genetic engineering techniques. One of the major strategies for producing next-generation CAR T cells involves the integration of useful co-factor(s) into the artificial genetic design of the CAR gene, resulting in next-generation CAR T cells that express both CAR and the co-factor(s). Many soluble co-factors have been reported for CAR T cells and their therapeutic effects and toxicity have been tested by systemic injection; therefore, CAR T cells harnessing secretory co-factors could be close to clinical application. Here, we review the various secretory co-factors that have been reported to improve the therapeutic efficacy of CAR T cells and ameliorate adverse events. In addition, we discuss the different co-factor expression systems that have been used to optimize their beneficial effects. Altogether, we demonstrate that combining CAR T cells with secretory co-factors will lead to next-generation CAR T-cell therapies that can be used against broader types of cancers and might provide advanced tools for more complicated synthetic immunotherapies.

KEYWORDS
CAR T cell, secretory co-factor, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), tumor microenvironment, solid tumor, synthetic biology
Introduction

Adoptive T-cell therapies with genetic engineering to express chimeric antigen receptors (CARs) have demonstrated remarkable efficacy in patients with some B-cell malignancies and multiple myeloma (1–6). Despite successful outcomes against these specific blood tumors, CAR T-cell therapies have proven much less effective against solid tumors due to tumor heterogeneity, physical barriers preventing T-cell infiltration, and immunosuppressive tumor microenvironments (TMEs) (7). In addition, currently approved CAR T-cell therapies are associated with safety issues such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) (8). The “on-target/off-tumor” activity of CAR T cells can cause life-threatening events in some cases (9–11); therefore, it is important to develop tumor-specific CAR T-cell therapies that target novel antigens.

To overcome the issues related to current CAR T-cell therapies, numerous co-factor-expressing CAR T cells have been investigated. These co-factors can be categorized into three types based on protein localization: (i) secretory factors released by CAR T cells can affect the CAR T cells themselves as well as surrounding cells expressing a receptor for the factor; (ii) membrane proteins penetrate or associate with the CAR T-cell membrane and affect the CAR T cells and surrounding cells through ligand binding; (iii) intracellular factors such as transcription factors affect the CAR T cell itself by regulating the expression of numerous genes to dramatically change the state of the cell [e.g., Yamanaka factors: from a differentiated cell to an inducible pluripotent cell (12)]. Secretory factors are usually used to recruit other cells and/or affect cells in a wider area in a contact-independent manner, unlike membrane proteins. Moreover, secretory factors can improve the ex vivo expansion of CAR T cells (13), suggesting that they can be used to manufacture advanced CAR T cells. Because secretory factor genes are generally much smaller than those of membrane proteins, they can even be included in viral vectors with strict transgene size limits. In addition, the majority of candidate co-factors (cytokines and antibodies) have already been tested in animal models or clinics from biological and clinical perspectives (Figure 1, Tables 1, 2). Finally, we describe current knowledge of constitutive and inducible types of co-factor expression machinery which could overcome some of the issues of current CAR T-cell therapies.

Challenges of current CAR T-cell therapies

Adverse events: CRS and ICANS

The clinical success of CD19-directed CAR T cells has also been accompanied by various limitations. CRS, the most common adverse event of CAR T-cell therapies, is caused by the overproduction of proinflammatory cytokines and mainly correlates with tumor burden (8). It has recently been suggested that during CRS, CD40L on CAR T cells and factor(s) from dead cells known as “danger signals” stimulate monocytes/macrophages to release interleukin-1 (IL-1) (41, 50). In addition, granulocyte-macrophage colony-stimulating factor (GM-CSF) from CAR T cells stimulates monocytes/macrophages to simultaneously proliferate at the inflammatory site (41, 43, 51). After IL-1 overproduction, the monocytes/macrophages produce IL-6, which plays a pivotal role in CRS (50). Current clinical protocols to treat CRS include glucocorticoids and/or IL-6 blockade (tocilizumab) (1, 52), whereas preemptive or early intervention with tocilizumab has been reported to prevent severe CRS (53, 54). IL-1 blockade (anakinra) is another promising strategy that is currently in clinical trials (55). ICANS is a severe and life-threatening adverse effect of CAR T-cell therapy (56, 57); however, the induction mechanisms remain unclear and few working therapeutic protocols have been verified. Although ICANS is associated with early systemic inflammation and CRS, the rate of which can be decreased through early intervention with tocilizumab, this therapeutic strategy does not affect the frequency of severe ICANS (58, 59). Conversely, prophylactic or early intervention with high-dose anakinra has yielded promising results against ICANS (55, 60). Together, these findings suggest that constitutive IL-6 and IL-1 blockade during CAR T-cell therapy may prevent CRS and ICANS, respectively.

Antigen specificity: “On-target, off-tumor” effects

Another limitation of CAR T-cell therapy is specificity. As of March 2022, four of the six CAR T-cell therapies approved by the U.S. Food and Drug Administration target CD19 as a tumor marker (1–4), whereas the others target B-cell maturation antigen (BCMA) (5, 6). To expand their application, it is necessary to develop CAR T-cell therapies targeting new antigens; however, a lack of specificity can lead to “on-target, off-tumor” effects which cause life-threatening toxicity depending on the non-pathogenic cell type(s) that express the
target antigen. For instance, a patient who received CAR T cells targeting the tumor antigen human epidermal growth factor receptor 2 (HER2) experienced rapid respiratory failure, multi-organ dysfunction, and subsequent death due to reactivity against pulmonary epithelia with slight HER2 expression (10). This issue could be solved by CAR T-cell strategies that can clearly discriminate between cancer cells and normal cells based on an antigen density threshold, since tumor-associated antigens are expressed at much higher levels in tumors than in normal tissues (61). In addition, AND logic could be applied to produce (A AND B) CAR T cells that can recognize cells expressing both antigens A and B, but not cells expressing only A or B (46, 62, 63). Even if neither antigen is specific to the tumor, the simultaneous expression of both antigens could be tumor-specific and thus limit “on-target, off-tumor” effects.

**Efficacy against solid tumors**

The other major limitation of CAR T-cell therapies is their ability to fight solid tumors, which is reduced by intratumor heterogeneity, an immunosuppressive TME, and/or physical barriers (7). Intratumor heterogeneity makes it difficult to identify appropriate tumor-specific antigens. Although non-engineered T cells can be primed to react to neoantigens or tumor-associated antigens, they are usually suppressed by components of the TME, such as regulatory T (Treg) cells and immune checkpoint ligands. Because the TME also interferes with CAR T-cell activity, numerous studies have attempted to modify the interaction between CAR T cells and the TME. For instance, programmed cell death protein 1 (PD-1) knockout CAR T cells can avoid PD-1–PD-L1 (programmed death-ligand 1) immune checkpoint signals (64), whereas dominant-negative transforming growth factor–β (TGF-β) receptor–expressing CAR T cells can attenuate Treg maintenance by blocking TGF-β (65). The TME also has much lower levels of homeostatic T-cell–supportive cytokines than lymphoid tissues, which may explain the limited persistence of tumor-infiltrating CAR T cells and tumor-reacting T cells. Indeed, CAR T cells that produce IL-7 and CCL19 to mimic T-zone function in lymphoid tissues have been reported to exhibit strong efficacy in animal solid tumor
models, mastocytoma cell line–derived xenografts (CDXs), hepatocellular carcinoma (HCC) patient-derived xenografts (PDXs), and pancreatic carcinoma CDXs (32, 33). Prior to their activation, intratumor CAR T cells and tumor-reacting T cells must penetrate and survive in tumors; however, the stromal structure of solid tumors acts as a physical barrier to protect against T-cell infiltration. CAR T cells harnessing the extracellular matrix-degrading enzyme heparanase are expected to improve tumor infiltration (66).

### TABLE 1 List of reported CAR T cells harnessing secretory co-factors.

| Secretory co-factor | Promoter | CAR target | Ref |
|---------------------|----------|------------|-----|
| **Aim: To enhance efficacy** | | | |
| IL-12 | 6x NFAT-RE | CEA | (14) |
| IL-12 | LTR in RVV | CD19 | (15) |
| IL-12 | 6x NFAT-RE | GPC3 | (16) |
| IL-12 | LTR in RVV | MUC16<sup>exo</sup> | (17, 18) |
| IL-12 | Endogenous CD25 promoter | CD22 | (19) |
| IL-18 | LTR in RVV | CD19 | (20) |
| IL-18 | LTR in RVV | CD19 | (21) |
| IL-12 or IL-18 | 6x NFAT-RE | GD2 | (22) |
| IL-21 | 6x NFAT-RE | CD19 | (23) |
| IL-15 & IL-21 | LTR in RVV | GPC3 | (24) |
| IL-23 (IL-12p40) | LTR in RVV | GD2, B7-H3 | (25) |
| IL-36γ | LTR in RVV | CD19 | (26) |
| IL-15 | LTR in RVV | CLL-1 | (27) |
| IL-15 | LTR in RVV | GD2 | (28) |
| IL-15 | LTR in RVV | IL-15Rx2 | (29) |
| CD40 agonist | LTR in RVV | MSLN | (30) |
| IL-7 & CCL19 | LTR in RVV | CD20 | (31) |
| IL-7 & CCL19 | LTR in RVV | GPC3, MSLN | (32) |
| IL-7 & CCL21 | LTR in RVV | CLND18.2 | (33) |
| Anti-PD-1 scFv (E27) | LTR in RVV | CD19 | (34) |
| Anti-PD-1 scFv (E30) | LTR in RVV | EGF | (35) |
| Anti-PD-1 scFv | LTR in RVV | CD19 | (36) |
| Anti-PD-1–TGF-βRII ectodomain | LTR in RVV | CD19 | (37) |
| Anti-CD47, Anti-PD-L1, Anti-CTLA4 | LTR in RVV, CMV | PD-L1, EIIIB | (38) |
| Anti-PD-L1 scFv | LTR in RVV | CAIX | (39) |
| **Aim: To protect CRS** | | | |
| IL-1RA | LTR in RVV | CD19 | (40) |
| Anti-IL-6 and IL-1RA | LTR in RVV | CD19 | (41) |
| Anti-IL-6 scFv and IL-1RA | LTR in RVV | CD19, BCMA | (42) |
| **Aim: To make circuit** | | | |
| BiTE EGFR-CD3 | EF-1α | EGFRII | (43) |
| Various factors | Gal4-UAS (SynNotch) | CD19 | (44) |
| Anti-AXL zipFv | 4x NFAT-RE | HER2 | (45) |
| CD19–anti-Her2 bridge protein | CMV | CD19 | (46) |
| CD19–anti-CLEC12A bridge protein | MSCV | CD19 | (47) |

LTR, long terminal repeat; RVV, retroviral vector; NFAT-RE, nuclear factor of activated T cell response element; BiTE, bispecific T-cell engaging antibody; UAS, upstream activation sequence.

**Secretory co-factors for enhancing CAR T-cell efficacy**

**IL-12**

IL-12 is a proinflammatory cytokine that has been repeatedly reported as a co-factor for CAR T cells. IL-12 induces the differentiation of CD4<sup>+</sup> T cells into a helper T-cell (Th1) subtype that release interferon-γ (IFN-γ) and support the
cytotoxic activity of CD8+ T cells. Consequently, IL-12 was expected to improve CAR T-cell cytotoxicity; however, IL-12–expressing CAR T cells have been reported to enhance monocyte (23) and T cell (16) recruitment, macrophage antigen presentation (14), and CAR T-cell persistence (19) rather than their cytotoxicity. Local recombinant IL-12 delivery can reshape the immunosuppressive TME (67, 68) and several clinical trials for tumor therapies with recombinant IL-12 administration have been conducted in recent decades (69). Unfortunately, high-dose systemic IL-12 treatment can cause life-threatening adverse events (70, 71) and milder regimens had no effect on advanced renal cell cancer as they delivered insufficient local concentrations of IL-12 to the TME (71). CAR T cells can carry IL-12 into tumors and IL-12 expression systems with inducible promoters, such as nuclear factor of activated T cell (NFAT) promoter, may safely minimize systemic IL-12 leakage (14, 16, 23). Because IL-12 is the most clinically characterized CAR T-cell co-factor, it could reasonably be used in future CAR T-cell therapies.

IL-18

Like IL-12, IL-18 activates T_h1 and NK cells to proliferate and release IFN-γ (20). In addition, IL-18–expressing CAR T cells recruit and activate endogenous anti-tumor immune cells in the TME (22). A previous animal study has suggested that IL-18 expressed by CAR T cells are more effective against advanced pancreatic tumors than IL-12 (21). Although systemic IL-18 administration has been reported to exert moderate adverse effects in clinical trials (77), IL-18 could be a safer and more effective co-factor than IL-12. Combination therapy with CAR T cells and recombinant IL-18 would be more costly than monotherapy with IL-18–producing CAR T cells; however, the additional clinical benefits of IL-18–producing CAR T cells compared to the combination therapy, such as specific efficacy and reduced adverse events, must be explored.

IL-21

IL-21 is a cytokine derived from follicular helper T cells that promotes high-affinity immunoglobulin production by B cells, T_h1 and T_h17 differentiation, and CD8 T-cell proliferation (78). Recombinant IL-21 supplementation has been reported to maintain an early memory T subtype during ex vivo CAR T-cell expansion (24). Although CAR T cells with activation-dependent IL-21 secretion (NFAT promoter-IL-21) displayed increased tumor infiltration in a chronic lymphocytic leukemia CDX model, no obvious improvement in anti-tumor efficacy has been reported (24). However, CAR T cells with constitutive expression of both IL-15 and IL-21 improved potency in a HCC

| ICBs | CAR target | Sponsor | Phase | ClinicalTrials.gov ID | Report |
|------|------------|---------|-------|-----------------------|--------|
| Anti–PD-1 | MUC1 | Shanghai Cell Therapy Research Institute | 1/2 | NCT03179007 | |
| Anti-CTLA4 | | | | | |
| Anti–PD-1 | EGFR | Shanghai Cell Therapy Research Institute | 1/2 | NCT03182816 | (49) |
| Anti-CTLA4 | | | | | |
| Anti–PD-1 | MSLN | Shanghai Cell Therapy Research Institute | 1/2 | NCT03182803 | |
| Anti-CTLA4 | | | | | |
| Anti–PD-1 | MSLN | Ningbo Cancer Hospital | 1/2 | NCT03030001 | |
| Anti-PD-1 | EGFR | Ningbo Cancer Hospital | 1/2 | NCT02873390 | |
| Anti–PD-1 | EGFR | Shanghai International Medical Center | 1/2 | NCT02862028 | |
| Anti–PD-1 | EGFRvIII | Shenzhen Geno-Immune Medical Institute | 1/2 | NCT03170141 | |

Okuma et al. 10.3389/fimmu.2022.907022
CDX (25). To proceed to the clinical application, IL-21 needs further study to explore the optimal cytokine combination.

**IL-23**

IL-23 has recently been reported as a promising secretory co-factor for CAR T cells (26). IL-23 is composed of two subunits: p40 (shared with IL-12) and p19. In activated T cells, the IL-23 receptor and p19 subunit are upregulated, but not the p40 subunit; therefore, Ma et al. engineered CAR T cells to express p40 to compensate for the cell-autonomous IL-23–IL-23R axis (26). These p40-expressing CAR T cells not only had a better safety profile but also displayed better efficacy against neuroblastoma and pancreatic cancer CDXs by promoting antigen-dependent proliferation and CAR T-cell persistence compared to IL-15 or IL-18. The data of this head-to-head study are valuable, and IL-23 should be tested with various types of CAR T cells to prove the concrete superiority of IL-23.

**IL-36γ**

IL-36 is a member of the IL-1 superfamily, like IL-18, that stimulates the NF-κB/AP-1 signaling pathway. The IL-36 receptor complex, which is composed of IL-36R (also known as IL-1RL2) and IL-1RAP, is expressed on epithelial cells, myeloid cells, and T cells. In terms of tumor immunity, IL-36 can induce anti-tumor immune responses, including the activation of Tγ1 (79), CD8+ T, γδT, and NK cells (80). In a recent study, IL-36γ-producing CAR T cells exerted superior therapeutic efficacy in leukemia xenograft and allograft mouse models through CAR T-cell self-activation and antigen-presenting cell activation (27); however, their effects against solid tumors have not yet been reported.

**IL-7 and CCL19 or CCL21**

IL-7 and CCL19 secreted from T-zone fibroblastic reticular cells recruit endogenous immune cells such as T cells and dendritic cells (DCs) from the periphery. To fight heterogeneous tumor cells, it is considered to be important to make the TME “hot” by recruiting endogenous immune cells; therefore, IL-7 and CCL19 have been combined as secretory co-factors for CAR T cells in a mastocytoma model (32). IL-7- and CCL19-expressing (7 × 19) CAR T cells showed a stronger therapeutic effect against mouse mastocytoma with increased endogenous DC and T-cell infiltration (32). A clinical trial of advanced carcinoma with glypican-3 or mesothelin expression found that two of the six patients had a complete or partial response to 7 × 19 CAR T-cell treatment without CRS or ICANS (33). Most recently, IL-7– and CCL21-expressing (7 × 21) CAR T cells were reported to yield better efficacy than 7 × 19 CAR T cells in mouse solid tumor models of pancreatic carcinoma, breast cancer, and HCC without preclinical lymphodepletion (34). Importantly, more DCs and T cells and fewer blood vessels were observed at the tumor sites of mice treated with 7 × 21 CAR T cells. CCL21 shares the same receptor (CCR7) with CCL19; however, the differential ability of CCL19 and CCL21 for desensitizing CCR7 (81) and/or the ability of CCL21 for binding other receptors like CXCR3 might cause the differential anti-tumor potency.

**Anti-PD-1/PD-L1**

The major immune inhibitory receptor PD-1 and its ligand PD-L1 are molecular targets of immune checkpoint blockade (ICB) therapies for various tumors (82–84); however, the therapeutic efficacy of these therapies depends on the TME immune status and the frequency of somatic mutations/neoantigens in tumor cells (83, 85, 86). CAR T cells could be an ideal booster to expand the applications of PD-1/PD-L1 ICB as they can recognize non-mutated proteins rather than neoantigens and can trigger endogenous immune reactions against tumors. In addition, ICBs could improve the persistence and efficacy of CAR T cells by altering the immunosuppressive TME (86–88). Clinical investigations of therapies combining CAR T cells and systemic ICBs are currently ongoing (89) and CAR T cells that secrete PD-1/PD-L1 blockades are also in development (35–40). Indeed, CAR T cells secreting PD-1 blockades have shown better results in a mouse model of pulmonary mucoepidermoid carcinoma than CAR T cells alone or CAR T cells combined with systemic PD-1 blockade (37). Several PD-1/PD-L1 blockade-secreting CAR T cells have been developed and are currently in clinical trials (Table 2) (90). Other approved ICBs against the inhibitory receptors CTLA-4 (84) and LAG-3 (91) and the upcoming ICB-targeting CD47, which inhibits phagocytosis-mediated cancer cell removal (92–94), may be also good CAR T-cell co-factors. Thus, the optimal co-factors for each cancer could be selected based on existing evidence from ICB monotherapies.

**IL-1 and/or IL-6 blockade to protect against CRS and ICANS**

Treatment with the anti–IL-6 drug, tocilizumab, can prevent CRS in mouse models but not abolish neurotoxicity (41, 50), whereas the natural IL-1 receptor antagonist (IL-1RA; human IL-1RA also known as anakinra) can prevent severe CRS and fatal neurotoxicity. To maximize the preventative effects of IL-1 blockade, mouse IL-1RA has been utilized as a secretory co-factor for CAR T cells that reduced CRS-related mortality without decreasing anti-tumor activity in a mouse model of
Engineered antibodies to redirect bystander T cells or CAR T cells

Bispecific T-cell engager (BiTE) is a tool that can be used to redirect T cells to attack tumor cells by acting as a bridge between CD3 and a target antigen (Figure 1B right). To achieve both tumor specificity and overcome tumor heterogeneity, EGFRvIII CAR T cells expressing BiTE against EGFR were developed against glioblastoma (44). EGFRvIII is a glioblastoma-specific tumor antigen and EGFR is highly expressed in glioblastoma and normal tissues, such as skin, but not in normal brains. EGFRvIII CAR acted as an anchor to the tumor, whereas EGFR-targeted BiTE redirected both CAR T cells and bystander T cells to attack the heterogeneous tumor. In addition, bicistronic CAR T cells have demonstrated potent and specific efficacy against heterogeneous tumors in animal models of glioblastoma (44).

This strategy can be applied to strict intercellular circuits by changing the co-factor and its expression machinery. For instance, in SUPRA platform, the CAR stimulus-inducible NFAT promoter was utilized to express an engineered antibody, AXL zipFv, that acts as a bridge between T cells expressing the compatible chimeric receptor zip CAR and the tumor antigen AXL (46). An intercellular AND gate (inputs, HER2 and AXL; output, receiver cell activation) was developed using sender cells harnessing HER2 CAR and the NFAT-AXL zipFv cassette and receiver cells harnessing the compatible zipCAR that were co-cultured with HER2 and AXL double-positive cells (Figure 2A). Beyond conventional CAR T-cell therapies, these synthetic biology techniques can engineer beneficial cell-cell communication via artificial secretory factors.

Another strategy utilizing recombinant CD19-containing bridging proteins (CD19-BPs) can redirect CD19 CAR T cell itself (Figure 2B) (47, 48). CD19 CAR T cells that secrete CD19-BP–targeting HER2 killed HER2-positive cells and CD19-positive cells (OR gate) and showed the comparable efficacy to HER2 CAR T cells in an ectopic HER2-positive ovarian cancer CDX model (47). In AML CDX models, CD19 CAR T cells that secrete CD19-BP–targeting CLEC12A exhibited the similar anti-tumor activity to CLEC12A-targeting CAR T cells (48). Like the BiTE secretion system, this system might be useful to tackle tumor heterogeneity and relapse due to antigen escape. CD19-BPs might have stronger effect than BiTE in that CAR signal is leveraged, although CAR T-cell exhaustion caused by repeated stimulation would be a concern in this system.

Co-factor expression machineries

Constitutive expression

Utilizing a strong constitutively active promoter can be the best way to maximize the expression of secretory co-factors. Compared to systemic administration, the area of co-factor efficacy can be regulated by CAR T-cell localization, even if they produce the co-factor at very high levels, thereby reducing the side effects of the co-factor. Despite the remarkable anti-tumor efficacy of IL-12 in various animal models, clinical trials of recombinant IL-12 showed severe toxicity, including mortality (70, 95). Therefore, various localized IL-12 delivery strategies that could be more effective and less toxic, including IL-12–expressing CAR T cells (15, 17, 18), are currently in clinical trials (96).

Since retrovirus vectors are generally used for T-cell transduction, the expression of secretory co-factors and CAR is often driven by the retroviral long terminal repeat (LTR) promoter or the CMV (cytomegalovirus), EF1α (elongation factor 1α), PGK (phosphoglycerate kinase), and SFFV (spleen focus-forming virus) promoters (97–100). In many cases, the EF1α and SFFV promoters are stronger, but do not always lead to a better transcriptional activity. In addition, CAR overexpression can lead to tonic signals and premature exhaustion (100, 101). Various gene drivers can be constructed by combining promoters, introns, and enhancers and can be optimized for the application of interest.

NFAT promoters

To avoid the unexpected effects of co-factors, inducible CAR/TCR activation–inducible promoters with low background activity have been used to localize co-factor delivery. NFAT promoters including NFAT response elements (REs) are widely used to monitor TCR activation. For instance, an NFAT promoter driving IL-12 secretion from ex vivo expanded tumor-infiltrating lymphocytes (TIL) was tested for metastatic melanoma clinical therapy (102). Clinical toxicity was still observed after high-dose infusion, possibly due to non-localized TILs with unknown TCR stimulation. Combining NFAT promoters with CARs could allow better control over the input signal to reduce unexpected co-factor expression. IL-12 and IL-18 have been selected as co-factors to be induced by NFAT promoters (14, 16, 23) due to their...
systemic toxicity, which can cause fever, leukopenia, and on-study death (20, 70, 71). However, there is concern that the NFAT promoter might not be strong enough to express less toxic co-factors, such as PD-1 blockades and anti–IL-6.

Increasing the number of NFAT-RE repeats (103) and changing the minimal promoter (23) have been reported to improve the NFAT promoter, resulting in stronger induction of the fluorescent reporter EGFP. Thus, customized NFAT promoters could have various applications.

Inducible constructs, such as the CAR and NFAT co-factor system, tend to involve the loading of a larger fragment that contains two promoter-coding gene cassettes: a constitutively active promoter, CAR, an inducible promoter, and a co-factor. Transposon systems can insert a much larger DNA fragment into the genome than viral vectors with a strict transgene size (104). Indeed, the transposon system piggyBac has been used to engineer CAR T cells harnessing NFAT–IL-21 instead of viral vectors (24). Large gene transfer techniques such as these could therefore be used to improve gene therapies by allowing them to become more complex and contain multiple gene cassettes.

**NR4A promoter**

The CAR/TCR-inducible NR4A promoter has been reported to have a comparable maximum activity but greater sensitivity than the conventional NFAT promoter (105). CAR T cells with the NR4A promoter showed greater responses when they met cancer cells with low target antigen expression. In addition, the NR4A promoter improved poorly responsive CAR T cells by inducing the higher expression of T-cell–supportive cytokines. Therefore, the NR4A promoter could expand the applications of co-factor–harnessing CAR T cells by improving the co-factor expression in non-ideal situations such as CAR T cell against a weakly immunogenic target and poorly responsive CAR T cells derived from chemotherapy-received patients.

**FIGURE 2**

Synthetic biology tools to make circuits by secretory co-factors. (A) Schematics of intercellular AND gate with the SUPRA CAR platform: A HER2 CAR-expressing sender cell secretes AXL zipFv in a CAR stimulus–dependent manner using the NFAT promoter. When AXL zipFv bridges a zipCAR-expressing receiver cell and AXL on a target cell, the receiver cell is activated. (B) Schematics of OR gate with a CD19 bridge protein (CD19-BP). This engineered cell expresses both CD19 CAR and the CD19-BP that is composed of recombinant CD19 and anti-HER2 scFv. Secreted CD19-BP engages CD19 CAR and a HER2-expressing target cell. (C) Schematics of how synNotch induces a co-factor. Upon ligand recognition by the synNotch receptor, a transcription factor (TF) integrated in the synNotch cytoplasmic domain is cleaved and released. The released TF induces the expression of a custom co-factor.
Endogenous promoters

Genome-editing technologies have enabled us to generate CAR T cells in which an endogenous promoter drives CAR expression. Utilizing well-characterized endogenous promoters can not only strictly regulate CAR expression but also that of multiple additional transgenes. CAR is usually inserted in the TRAC locus, which encodes TCRβε. This produces uniform and cell type-specific CAR expression (19, 106, 107) that enhances CAR T-cell potency without unexpected differentiation and exhaustion. Sachdeva et al. reported CAR T cells producing IL-12 under the control of CD25 or PD-1 regulatory elements (19), suggesting that various promoter types can be applied to express co-factors. Therefore, endogenous promoters and highly efficient techniques for gene transfer and transgene genome integration should be validated.

Other synthetic promoters

Hypoxia-inducible promoters are often used for hypoxic TME-specific CAR expression and are composed of hypoxia-responsive elements that allow HIF1α-dependent transcription under low oxygen conditions (108, 109). To recognize the TME through both hypoxia and inflammation, synthetic promoters composed of multiple consensus promoter response element sequences for IFN-γ, TNF-α, and hypoxia were tested in human T cells (110). In vitro experiments confirmed additive gene expression due to IFN-γ, TNF-α, and hypoxia; thus, synthetic promoters could provide CAR T cells with artificial genetic circuits that can allow more complex therapeutic applications.

SynNotch

The SynNotch system is a type of molecular switch for artificial gene circuits that is composed of an extracellular antigen recognition domain (single-chain variable fragment, scFv), a Notch core regulatory region, an engineered transcriptional factor as an intracellular domain, and a gene expression cassette with a promoter that is compatible with the transcription factor (111). Once scFv recognizes the antigen on target cells, the Notch core is cleaved by a metalloprotease and γ-secrectase. The transcription factor is released and translocated to the nucleus, triggering the transcriptional activation of the gene of interest (Figure 2C). Roybal et al. developed T cells to express CAR after synNotch receptor activation as a combinatorial antigen-sensing system (AND gate) (63). The synNotch system was subsequently modified so that the engineered cells could secrete diverse therapeutic factors in an antigen-specific manner (45, 112). Because synNotch itself does not induce CAR/TCR activation, the system could be used for the local delivery of biologics rather than amplifying CAR T-cell efficacy. In addition, synNotch allows stronger gene induction and more precise control of signal pathways than other inducible promoters like the NFAT promoter. An artificial transcription factor consisting of a Gal4 DNA binding domain fused to a tetrameric VP64 viral transcriptional activator domain (Gal4-VP64) is often used and has great transcriptional activity. Gal4-VP64 specifically binds to an upstream activation sequence (UAS) and induces downstream gene expression. Artificial transcriptional factors like Gal4-VP64 can minimize the unexpected activation of non-target genes and crosstalk between synNotch signaling and native signaling. One of the disadvantages of the synNotch system is immune rejection due to non-human-derived components; however, this can be avoided using fully humanized synNotch synthetic intramembrane proteolysis receptors (SNIPRs), which are expected to enter clinical use shortly (113).

Discussion

Various secretory co-factor–expressing CAR T cells are under development to improve their anti-tumor efficacy and safety. It is difficult to directly compare the ability of secretory co-factors to enhance the efficacy of CAR T cells against solid tumors because no ideal animal models of human solid tumors have yet been established. However, ICBs, IL-12, IL-15, and IL-18 have the advantage of existing clinical data for their recombinant administration in patients with advanced or metastatic solid tumors (69, 71, 76, 77). Indeed, several clinical trials of PD-1– or PD-L1–secreting CAR T-cell therapies are ongoing in China (Table 2), and we anticipate that at least one of these cytokines will be tested as a co-factor for CAR T cells in the near future. Due to the abundance of different types of solid tumors, multiple CAR T-cell types should be developed to allow clinicians to make the best therapeutic choice for each patient. For instance, IFN-γ enhances ICAM-1–mediated CAR T-cell cytotoxicity against various types of solid tumor but not the leukemia, lymphoma, or myeloma CDX models (114), although this different IFN-γ sensitivities are unclear in clinical level. In addition, multiple cytokines and ICBs can be loaded onto a CAR construct to exert additive or synergistic effects against more tumor types. IL-7 and CCL19/CCL21 combinations, which are intended to recruit and maintain nonengineered immune cells, are leading the race for optimal co-factor combinations for CAR T-cell therapies (32–34); however, various co-factor combinations must be tested after single co-factor CAR T-cell clinical trials.

In terms of genetic engineering, wherein the co-factor gene is added to a CAR-coding construct, “next-generation” CAR T cells are expected to have equivalent or even better efficacy than promising combination therapies involving the same factor without additional administration. To maximize clinical outcomes, the automated regulation of the amount and timing
of co-factor expression could be the next development focus. For instance, IL-6 and IL-1 blockers are promising co-factors to prevent CRS; however, their constitutive expression might be problematic due to unexpected immunosuppressive effects. “CAR T-cell activation–dependent” or “tumor site–specific” expression machineries could solve this issue. Although weak NFAT promoter activity is the biggest concern for activation-dependent machinery, the modification of the NFAT promoter and the newly verified NR4A promoter could enhance maximum co-factor production. SynNotch is a synthetic biology solution for antigen-dependent high co-factor expression, whereas hypoxia-inducible promoters can achieve site-specific expression to maximize co-factor efficacy. In addition, genome-editing techniques could produce various types of endogenous promoters that could be used simultaneously to control multiple co-factors.

To regulate the spatial range of effects more strictly, synthetic chimera forms of cytokines have also been reported. Membrane-bound cytokines are chimera forms fused to a transmembrane domain or a cell surface receptor. Expressing the membrane-bound cytokines is intended to enhance the potency of engineered cells themself and minimize the effect on surrounding cells, which is supposed to work as a conditioned culture even in vivo (115–117). Therefore, this strategy could strongly support recently spotlighted fast CAR T-cell manufacturing procedures that expect in vivo expansion of CAR T cells instead of conventional ex vivo expansion (118, 119). Another synthetic chimera form of cytokines is a target-tethered cytokine composed of a cytokine and an antibody fragment or a specific binding domain (68, 120). TME-specific accumulation or immune cell–specific tethering can enhance the anti-tumor efficacy of IL-12 while limiting systemic toxicities. Similar to BiTE, zipFv-zipCAR, and CD19-BP (in Section 4), this approach could be applied to CAR T-cell therapy as a secretory co-factor that plays an immunomodulatory role in synthetic cell-cell communication.

In summary, synthetic biology approaches could expand the T-cell engineering tool kit and enable CAR T cells to be programmed with more complex functionality. Beyond cancer therapy, future secretory co-factors could enable synthetic communication between engineered cells and nonengineered cells or among engineered cells to build a synthetic immune cell consortium. Altogether, combining CAR T cells with secretory co-factors will lead to next-generation CAR T-cell therapies against broader types of cancers and provide advanced tools for more complicated synthetic immunotherapies.

Author contributions
AO, YI, TK, SH, and SA prepared the manuscript. All authors contributed to the article and approved the submitted version.

Funding
AO was supported by Leading Initiative for Excellent Young Researchers grant from Japan Society for the Promotion of Science.

Conflict of interest
AO, YI, TK, SH, and SA are currently full-time employees at Hitachi, Ltd.

Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References
1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory Large b-cell lymphoma. N Engl J Med (2017) 377(26):2531–44. doi: 10.1056/NEJMoA1707447
2. Maude SL, Laetsch TW, Burcher J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med (2018) 378(5):439–48. doi: 10.1056/NEJMoA1709866
3. Abramson JS, Palemon ML, Gordon LI, Lunning MA, Wang M, Arnaud J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL-001): a multicentre seamless design study. Lancet (2020) 396(10254):839–52. doi: 10.1016/S0140-6736(20)31366-0
4. Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, et al. Bremcabtagene autoleucel for Relapsed/Refractory mantle cell lymphoma: Real world experience from the US lymphoma CAR T consortium. Blood (2021) 138:744. doi: 10.1182/blood-2021-147563
5. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lenial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med (2021) 384(8):705–16. doi: 10.1056/NEJMoA2024850
6. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Gilvacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma.
expression of IL-12 enhances antitumor activity of Glypican-3 tumor antigen expression. Antigen-independent macrophage response on tumor cells that have shut down engineered T cells expressing chimeric antigen receptors can effectively muster an coexpression.

Frontiers in Immunology frontiersin.org

Okuma et al. 10.3389/fimmu.2020.10.20124

11. Baroni ML, Martinez DS, Aguera FG, Ho HR, Castella M, Zanetti SR, et al. 41BB-based and CD28-based CD123-directed T cells ablate human normal hematopoiesis in vivo. J Immunother Cancer (2020) 8(1):e001995-6. doi: 10.1038/s41943-020-0280-9.

12. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy in vivo. J Immunother Cancer (2021) 9(1):2018-0041-7.

13. Lamers CHJ, Sleijfer S, Metelitsa L, Dotti G, Savoldo B. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin Cancer Res (2019) 25(9):2918-24. doi: 10.1158/1078-0432.CCR-18-1811.

14. Kano K, Tanaka H, Nakumi H, Marita N, Ichikawa T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 131(3):461-72. doi: 10.1016/j.cell.2007.11.019.

15. Peagram HJ, Lee JC, Hayman EG, Imperato GH, Todd TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 119(14):4313-41. doi: 10.1182/blood-2011-12-40044.

16. Liu Y, Di S, Shi B, Zhang H, Yang W, Wu X, et al. Armored inducible expression of IL-12 enhances antitumor activity of Glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J Immunol (2019) 203(1):198-207. doi: 10.4049/jimmunol.1800033.

17. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. OncoImmunology (2015) 4(3):e994446. doi: 10.1016/j.oncotarget.2014.994446.

18. Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B. Eradication of advanced hematologic malignancy. J Transl Med (2021) 19(1):82. doi:10.1186/s12967-021-02750-4.

19. Xie YJ, Dougan M, Ingram JR, Pishesha N, Fang T, Momin N, et al. Clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed T cells engineered to secrete CD40 antibodies enhance antitumor efficacy. J Transl Med (2018) 26(20):5489-505. doi: 10.1186/s12967-018-00777-6.

20. Luo H, Li S, Ou Y, Wang T, Fang Y, Ding Y, Qian Q. Chimeric antigen receptor T cells engineered to secrete CD40 antibodies enhance antitumor efficacy. J Transl Med (2019) 17(1):81. doi:10.1186/s12967-019-02276-2.

21. Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-bethigh effectors that exhibit augmented activity against advanced solid tumors. Cell Rep (2018) 23(7):2106-41. doi: 10.1016/j.celrep.2018.04.051.

22. Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung PH. Inducible cytokines improve CAR-T cell functionality and induces endogenous antitumor response. J Immunother Cancer (2020) 8(1):e000845. doi: 10.1136/jitc-2020-000845.

23. Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, et al. IL-7 and CCL19-secreting CAR T cell therapy for tumors with positive glucagon 3 or mesothelin. J Hematol Oncol Hematol Oncol (2021) 14(1):118. doi:10.1186/s13045-021-01128-9.

24. Li S, Sirumon W, Zhang X, Yang S, Jin T, He F, et al. Enhanced cancer immunotherapy by chimeric antigen receptor-engineered T cells with advanced logic and distributed computing in human CAR immune cells. Nat Biotechnol (2020) 38(4):448-55. doi: 10.1038/s41587-019-0398-2.
Decreased rates of severe CRS seen with early intervention strategies for CD19 axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with b-cell acute lymphoblastic leukemia. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with refractory lymphoma. A prospective clinical trial of tocilizumab after CAR-T cell therapy in patients with advanced renal cell cancer. Clinical Cancer Res Off J Am Soc Clin Oncol (2018) 24(8):2397–9. doi: 10.1158/1078-0432.CCR-17-2744.

Kadauke S, Gust J, Hay KA, Hana M, Tonai Y, et al. T Cell circuits that sense antigen density with an ultrasensitive activity against highly aggressive acute myeloid leukemia in vitro and antitumor activity against advanced renal cell cancer. J Clin Oncol Off J Am Soc Clin Oncol (2015) 33(1):74.

Leonard WJ, Wan CK. IL-21 signaling in immunity. F1000Research (2016) 5:F1000. doi: 10.12688/f1000research.7634.1.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. Nat Med (2015) 21(5):540–6. doi: 10.1038/nm.3833.

Agliardi G, Liuzzi AR, Hotblack A, De A, Foa D, Nüesch N, Stowe CL, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a preclinical model of glioblastoma. Nat Commun (2021) 12(1):444. doi: 10.1038/s41467-020-20599-x.

Mansurov A, Ishshara J, Housephill P, Potin L, Marchell TM, Ishihara A, et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat BioMed Eng (2020) 4(5):531–43. doi: 10.1038/s41551-020-0549-2.

Lasek W, Zapotokh R, Jakubisiak M, Interleukin 12 still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother (2014) 63(5):419–35. doi: 10.1007/s00262-014-1523-1.

Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 99(7):2541–8.

Portielje JE, Krut WH, Schuler M, Beck J, Lammers CH, Stoter G, et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res Off J Am Soc Clin Oncol (1999) 5(12):3983–9.

Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A. (2004) 101(7):1969–74. doi: 10.1073/pnas.0307298101.

Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their CAR-T cell dysfunction and differentiation. Cancers (2021) 13(4):5334. doi: 10.3390/cancers13143354.

Giuffrida L, Sek K, Henderson MA, House IG, Lai J, Chen AXY, et al. IL-15 pre-conditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol Ther (2020) 28(11):2379–97. doi: 10.1016/j.ymthe.2020.07.018.

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol (2015) 33(1):74–82. doi: 10.1200/JCO.2014.57.3329.

Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathan S, Kirby LC, et al. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res (2008) 14(11):3462–9. doi: 10.1158/1078-0432.CCR-07-4740.

Wong X, Zhao X, Feng C, Wrinstein A, Xia R, Wen W, et al. IL-36γ enhances CAR-T cell antitumor activity by reducing inhibitory CAR-mediated antitumor immune responses. Cancer Cell (2015) 28(3):296–306. doi: 10.1016/j.ccell.2015.07.014.

Nandagarol S, Wu D, Lin F. Combinatorial guidance by CCR7 ligands for T lymphocytes migration in Co-existing chemokine fields. PloS One (2011) 6(3):e18183. doi: 10.1371/journal.pone.0018183.

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol (2020) 20(11):651–66.

Vigne S, Palmer G, Martin P, Lamachica C, Srebel D, Rodrigues E, et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood (2012) 120(12):3478–87. doi: 10.1182/blood-2012-08-439026.

Schuler M, Beck J, Kruit WH, Schuler G, Schuler M, et al. Understanding the tumor immune microenvironment (TIME) for tumours with combination immunotherapies. Nat Rev Drug Discovery (2019) 18(1):1–21. doi: 10.1038/s41573-018-0007-y.

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery (2019) 18(3):197–218. doi: 10.1038/s41573-018-0007-y.
Okuma et al. 10.3389/e148. doi:10.1093/nar/gkr764

88. Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR T cell therapy in hematologic malignancies. J Hematol Oncol Hematol Oncol (2019) 12(1):59. doi:10.1186/s12017-019-0746-1

89. Ramello MC, Hauru EB, Abebe-Daga D. CAR-T cells and combination therapies: What’s next in the immunotherapy revolution? Pharmacol Res (2018) 129:194–203. doi:10.1016/j.phrs.2017.11.035

90. Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-t): Combination or built-in CAR-T. Int J Mol Sci (2018) 19(2):340. doi:10.3390/ijms19020340

91. Tawels HA, Schadendorf D, Lipson EJ, Ascieto PA, Matamala L, Castillo Gutierrez E, et al. Relatifubin and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med (2022) 386(12):1–34. doi:10.1056/NEJma2109970

92. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. G0 (2010) 142(2):699–713. doi:10.1016/j.cel.2010.07.044

93. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fatman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci (2013) 110(27):11103–8. doi:10.1073/pnas.1305691110

94. Sun J, Chen Y, Lubben B, Adebayo O, Muz B, Azab AK. CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies. Leuk Res Rev (2021) 16:100268. doi:10.1016/j.lrr.2021.100268

95. Huertheau J, Blessing JA, DeCesare SL, Cresman WT. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: A gynecologic oncology group study. Gynecol Oncol (2001) 82(1):7–10. doi:10.1006/gyno.2000.6255

96. Nguyen KG, Vrhal MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon RF, et al. Promoter (2017) 13(10):e1006613. doi:10.1371/journal.ppat.1006613

97. Juilleret A, Marechal A, Filhol M, Yegodayev K, et al. Synthetic promoters to induce immune-effectors into the tumor microenvironment. Commun Biol (2021) 4(1):1–11. doi:10.1038/s42003-021-01664-7

98. Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, PloS One (2021). doi:10.26502/jbb.2642-91280036

99. Anna F, Bole-Richard E, Fredon M, Certoux JM, Souque P, Garnache-Ottou P, et al. Design and modular assembly of synthetic intramembrane proteolysis receptors for custom gene regulation in therapeutic cells. [Internet]. bioRxiv. (2021). doi:10.1101/2021.05.21.244218v1

100. Lu A, Cluggitt RS, Wang Y, Liu P, Thomas RE, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci (2016) 113(48):E7788–97. doi:10.1073/pnas.1610544113

101. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell (2016) 164(4):780–91. doi:10.1016/j.cell.2016.01.012

102. Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med (2021) 3:7. doi:10.1016/j.xcrm.2021.100227

103. Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, J Cancer (2022) 11(4):1440. doi:10.1182/jcancer.100236

104. Bordonaro PJ, Intisar E, Junghans RP, Wong WW. Engineering ad specific CAR and SynNotch receptor for cancer therapy. Sci Rep (2018) 8(1). doi:10.1038/s41598-018-22256-2

105. Zhou L, Liu R, Hyrenius-Wittsten A, Piraner DI, Alavi J, Israfil DV, et al. Design and modular assembly of synthetic intramembrane proteolysis receptors for custom gene regulation in therapeutic cells. [Internet]. bioRxiv. (2021). doi:10.1101/2021.05.21.244218v1

106. Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, J Cancer (2022) 11(4):1440. doi:10.1182/jcancer.100236

107. Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, et al. One-step manufacturing of modular CAR-T cells with AAV-Cpf1. Nat Methods (2019) 16(4):780–91. doi:10.1016/j.cell.2019.07.044

108. Juilleret A, Marechal A, Filhol M, Yegodayev K, et al. Synthetic promoters to induce immune-effectors into the tumor microenvironment. Commun Biol (2021) 4(1):1–11. doi:10.1038/s42003-021-01664-7

109. Kosti P, Opzoomer JW, Larios-Martinez KL, Henley-Smith R, Scudamore CL, Okesola M, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med (2021) 3(1):70. doi:10.1016/j.xcrm.2021.100227

110. Greenshpan Y, Sharabi O, Ottolegni A, Cahana A, Kundu K, M. Yegodayev K, et al. Synthetic promoters to induce immune-effectors into the tumor microenvironment. Commun Biol (2021) 4(1):1–11. doi:10.1038/s42003-021-01664-7

111. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell (2016) 164(4):780–91. doi:10.1016/j.cell.2016.01.012

112. Cho JH, Okuma A, Al-Rubaye D, Intisar E, Junghans RP, Wong WW. Engineering ad specific CAR and SynNotch receptor for cancer therapy. Sci Rep (2018) 8(1). doi:10.1038/s41598-018-22256-2

113. Zhu I, Liu R, Hyrenius-Wittsten A, Piraner DI, Alavi J, Israfil DV, et al. Design and modular assembly of synthetic intramembrane proteolysis receptors for custom gene regulation in therapeutic cells. [Internet]. bioRxiv. (2021). doi:10.1101/2021.05.21.244218v1

114. Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llops PM, Bouffard AA, et al. CAR T cell killing requires the IFNγ pathway in solid but not liquid tumours. Nature (2022) 604(7906):563–70. doi:10.1038/s41586-022-04585-5

115. Hurton LV, Singh H, Najjar AM, Switzer KC, M'ti, M, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci (2016) 113(48):E7788–97. doi:10.1073/pnas.1610544113

116. Hombach A, Barden M, Hannappel L, Chmielowski M, Rappel G, Sachindras A, et al. IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Mol Ther - Oncolytics (2019) 12:16–25. doi:10.1016/j.omtn.2018.11.003

117. Yang J, He J, Zhang X, Wang Z, Zhang Y, Cai S, et al. A feasibility and safety study of a new CD19-directed fast CAR-T therapy for refractory and relapsed b cell acute lymphoblastic leukemia. Blood (2019) 134(Supplement_1):825–5. doi:10.1182/blood-2019-121751

118. Flinn IW, Jaeger U, Shah NN, Blaise D, Briones J, Shune L, et al. A frontiersin.org